Alpha 2.0
Login Register
» Journals » Drug Metab Pharmacokinet

Drug Metabolism and Pharmacokinetics

Drug Metabolism and Pharmacokinetics is a peer-reviewed scientific journal that focuses on the study of drug metabolism, pharmacokinetics, and drug-drug interactions. It publishes original research articles, reviews, and case reports, providing valuable insights into the absorption, distribution, metabolism, and excretion of drugs, as well as their effects on the body. The journal serves as a platform for researchers and practitioners to share advancements in understanding drug metabolism and pharmacokinetics, contributing to the development of safe and effective drug therapies.
Details
Abbr. Drug Metab Pharmacokinet
Publisher Elsevier
Start 2002
End Continuing
Frequency Bimonthly
p-ISSN 1347-4367
e-ISSN 1880-0920
Country United Kingdom
Language English
Specialties Pharmacology
Endocrinology
Metrics
h-index / Ranks: 4734 75
SJR / Ranks: 6612 674
CiteScore / Ranks: 6010 4.40
JIF / Ranks: 5004 2.1
Recent Articles
1.
Future direction of animal alternative/microphysiological systems in drug discovery and development
Arakawa H, Takayama K
Drug Metab Pharmacokinet . 2025 Mar; 61:101479. PMID: 40088575
No abstract available.
2.
Advanced in vitro evaluation of drug-induced kidney injury using microphysiological systems in drug discovery and development
Arakawa H, Matsushita K, Ishiguro N
Drug Metab Pharmacokinet . 2025 Mar; 61:101056. PMID: 40088574
Drug-induced kidney injury (DIKI) is a major cause of acute kidney injury (AKI). Given concerns about animal welfare and the need for more accurate prediction of human events, there is...
3.
Comprehensive invitro evaluation of the inhibitory effects of relatively high molecular weight peptides on drug-drug interaction-associated four liver transporters and its association with physicochemical properties
Ishikawa R, Misawa T, Demizu Y, Saito Y, Kikura-Hanajiri R, Saito K
Drug Metab Pharmacokinet . 2025 Mar; 61:101055. PMID: 40043642
In recent years, advances in peptide synthesis have enabled the construction of relatively high molecular weight (Mw; >1 kDa) peptides using various types of amino acids (AAs), including proteinogenic/natural and...
4.
Establishment of endogenous canine MUC1 knock-out MDCKII cells using CRISPR-Cas9 and evaluation of drug permeation
Kishimoto H, Miyazaki K, Omori M, Higuchi K, Shirasaka Y, Inoue K
Drug Metab Pharmacokinet . 2025 Feb; 61:101051. PMID: 39955894
Most orally administered drugs are absorbed by simple diffusion across the intestinal epithelium. Monolayers of MDCKII cells and parallel artificial membrane permeability assay are widely used to evaluate simple diffusion...
5.
Substrate inhibition potential of arachidonic acid on 14,15-epoxidation, a biological drug developmental target, mediated by recombinant human cytochrome P450 2J2 and 2C8 enzymes
Kojima A, Nadai M, Yamazaki H, Katoh M
Drug Metab Pharmacokinet . 2025 Feb; 61:101052. PMID: 39923279
Arachidonic acid is metabolized to biologically active (±)14(15)-epoxy-5Z,8Z,11Z-eicosatrienoic acid (14,15-EET), and suppression of this step is believed to be a drug developmental target in cancer treatment. Although the key 14,15-epoxidation...
6.
In vitro characterization of taurine transport using the human brain microvascular endothelial cell line as a human blood-brain barrier model
Tega Y, Kawauchi Y, Akanuma S, Inagaki M, Tachikawa M, Hosoya K
Drug Metab Pharmacokinet . 2025 Feb; 61:101040. PMID: 39923278
Taurine, a sulfur-containing β-amino acid, has various roles in the brain including cellular osmoregulation and neuroprotection. For adequate supply to the brain, taurine has to pass through the blood-brain barrier...
7.
Opportunities for microphysiological systems from the view of Japanese industries
Naraoka H, Iguchi T, Harada K, Usui T, Suwa Y, Ando M, et al.
Drug Metab Pharmacokinet . 2025 Jan; 60:101034. PMID: 39847981
Regulatory authorities and pharmaceutical companies in Europe and the United States have paid attention to microphysiological systems (MPS), and various consortia and academic societies have been established. They are actively...
8.
Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs
Kimura H, Nishikawa M, Kutsuzawa N, Tokito F, Kobayashi T, Kurniawan D, et al.
Drug Metab Pharmacokinet . 2025 Jan; 60:101046. PMID: 39847980
This study explored the evolving landscape of Microphysiological Systems (MPS), with a focus on organoids and organ-on-a-chip (OoC) technologies, which are promising alternatives to animal testing in drug discovery. MPS...
9.
Development and application of 3D cardiac tissues derived from human pluripotent stem cells
Ohno M, Tani H, Tohyama S
Drug Metab Pharmacokinet . 2025 Jan; 60:101049. PMID: 39847979
Recently human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate drug responses for cardiotoxicity testing and disease modeling. Moreover, three-dimensional (3D) cardiac models, such as engineered...
10.
Global expansion of microphysiological systems (MPS) and Japan's initiatives: Innovation in pharmaceutical development and path to regulatory acceptance
Yamazaki D, Ishida S
Drug Metab Pharmacokinet . 2025 Jan; 60:101047. PMID: 39847978
Microphysiological systems (MPS) are gaining global attention as potential game-changers in pharmaceutical development. Since 2013, MPS suppliers from university laboratories in the United States and Europe have competed to develop...